Ilene A. Galinsky

Hematology Oncology

44 Binney St # Dl189b
Dana Farber Cancer Institute
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Journal: Leukemia

Published: May 06, 2026

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal: Blood

Published: March 03, 2026

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Journal: Haematologica

Published: February 17, 2026

Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance).

Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance).

Journal: Blood advances

Published: January 08, 2026

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Journal: Blood advances

Published: January 08, 2026

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 22, 2025

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 22, 2025

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp.

Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp.

Journal: Journal of the advanced practitioner in oncology

Published: August 11, 2025

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Journal: Leukemia research

Published: April 18, 2025

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.

Journal: Blood cancer journal

Published: July 31, 2024

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.

Journal: Blood advances

Published: September 18, 2023

Showing 1-12 of 61

Last Updated: 09/26/2026